title: [Effects of Corbrin Shugan capsule on dimethylnitrosamine-induced hepatic fibrosis in rats].
abstract: OBJECTIVE
  To investigate the effects of Corbrin Shugan capsule on dimethylnitrosamine (DMN)-induced hepatic fibrosis in rats.
  
  
  METHODS
  Hepatic fibrosis was induced by DMN in AD rats. The serum concentrations of III pro-collagen (III PC),laminin (LN) and tissue inhibitor of metalloproteinase-1(TIMP-1) were determined with ELISA. The concentration of albumin (ALB) in sera and the content of hydroxyproline (Hyp) in liver tissues were determined with chemical colorimetric and HPLC, respectively. The fibrosis area was measured with Motic Med 6.0 digital medical image analysis system.
  
  
  RESULTS
  Compared to model group the high-dose (450 mg kg(-1)),mid-dose (270 mg kg(-1)) and low-dose (90 mg kg(-1)) groups of Corbrin Shugan capsule had significantly lower serum content of III PC [34.46 ± 13.95),(36.15 ± 9.46), and (40.58 ± 7.72)ng ml(-1) compared with (49.38 ± 10.95)ng ml(-1),P<0.05 or P<0.01],TIMP-1 [(16.65 ± 4.24),(16.66 ± 4.34),and (18.99 ± 6.05)ng ml(-1) compared with (30.84 ± 14.48)ng ml(-1), P<0.05 or P<0.01], LN [(12.94 ± 4.29), (12.96 ± 3.21),and (15.32 ± 8.00)ng ml(-1) compared with (30.22 ± 17.00)ng ml(-1),P<0.05 or P<0.01] and smaller hepatic fibrosis area [(0.02240 ± 0.01337), (0.02176 ± 0.01460) and (0.02384 ± 0.01405)μm(2) compared with vs (0.03929 ± 0.01732)μm2, P<0.05 or P<0.01]; the high-dose and mid-dose groups of Corbrin Shugan capsule had significantly lower content of Hyp in liver tissues [(0.77 ± 0.09) and (0.81 ± 0.09)μg μmg(-1) compared with (1.06 ± 0.33)μg mg(-1),P<0.05 or P<0.01]; and the high-dose group of Corbrin Shugan capsule significantly increased the content of ALB in sera [(34.02 ± 4.17)g L(-1) compared with (30.25 ± 4.21)g L(-1),P<0.05].
  
  
  CONCLUSIONS
  Corbrin Shugan capsule is effective in treatment of DMN-induced hepatic fibrosis in rats.
authors.affiliation: Department of Pharmacy, The Affiliated Obstetrics and Gynecology Hospital, Zhejiang University School of Medicine, Hangzhou 31006, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Qian
authors.forename: Xu-Chun
authors.initials: XC
authors.lastname: Fu
authors.forename: Rong
authors.initials: R
authors.lastname: Hu
authors.forename: Li-Mei
authors.initials: LM
authors.lastname: Shen
authors.forename: Hai-Bo
authors.initials: HB
authors.lastname: Bai
mesh_terms: D000418:Albumins / Q000378:metabolism; D000818:Animals; D002214:Capsules; D024061:Collagen Type III / Q000097:blood; D004128:Dimethylnitrosamine / Q000009:adverse effects; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D006909:Hydroxyproline / Q000378:metabolism; D007797:Laminin / Q000097:blood; D008106:Liver Cirrhosis, Experimental / Q000188:drug therapy*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood
chemical_list: D000418:Albumins; D002214:Capsules; D024061:Collagen Type III; D004365:Drugs, Chinese Herbal; D007797:Laminin; C576839:TIMP1 protein, rat; D019715:Tissue Inhibitor of Metalloproteinase-1; D004128:Dimethylnitrosamine; D006909:Hydroxyproline